Vitamin K1 for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Phylloquinone, Phytonadione, Phytomenadione, Vitamin K-1

Motivation

Vitamin K1 (phylloquinone) is the predominant dietary form of vitamin K, found in dark leafy greens such as kale, spinach, and Swiss chard. Best known as the cofactor that allows blood to clot, vitamin K1 also activates proteins involved in bone strength, arterial calcification control, and glucose metabolism, placing it among the nutrients of growing interest for long-term health.

A consistent observation in modern nutrition research is that many adults consume just enough vitamin K1 to maintain normal coagulation but not enough to fully activate the protective proteins in bone and the vascular wall — a state often described as subclinical insufficiency. This gap, combined with vitamin K1’s exceptional safety profile and low cost, has positioned it as a candidate nutritional lever for adults in midlife and beyond, when bone loss and arterial calcification accelerate.

This review examines the evidence on vitamin K1 status and supplementation, covering its mechanisms, benefits, risks, interactions, and practical protocols for adults pursuing a health and longevity strategy.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Phytomenadione

Detailed reference covering phytomenadione’s chemical structure (2-methyl-3-phytyl-1,4-naphthoquinone), its biosynthesis in plants, biological function as a cofactor for gamma-glutamylcarboxylase, dietary sources, and clinical use in treating vitamin K deficiency bleeding and reversing warfarin overdose.

Examine

Vitamin K

Comprehensive supplement page covering both vitamin K1 and K2, with evidence summaries across bone health, cardiovascular outcomes, and glucose metabolism, practical dosing guidance for phylloquinone, and information on fat-dependent absorption and food sources.

ConsumerLab

Vitamin K Supplements Review (Including Calcium, Vitamin D, Magnesium & Boron)

Independent testing of vitamin K supplements, including phylloquinone-only and combined K1/K2 products, with discussion of label-claim accuracy, cost per daily dose, and identification of “Top Picks” across product categories.

Systematic Reviews

Recent systematic reviews and meta-analyses examining vitamin K (including vitamin K1/phylloquinone) in humans.

Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis - Chen et al., 2019

Meta-analysis of 21 prospective studies pooling more than 220,000 participants. Higher dietary phylloquinone intake was significantly associated with lower risk of total coronary heart disease (pooled HR (hazard ratio, a measure of how often an event occurs in one group versus another) 0.92; 95% CI (confidence interval, the range within which the true value likely falls) 0.84–0.99). Elevated plasma dp-ucMGP (dephosphorylated uncarboxylated matrix Gla protein, a marker of vitamin K deficiency) was associated with substantially higher all-cause mortality risk.
Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts - Shea et al., 2020

Participant-level meta-analysis of 3,891 individuals followed for a median of 13 years. Low circulating phylloquinone (≤0.5 nmol/L) was associated with 19% higher all-cause mortality (HR 1.19; 95% CI 1.03–1.38) compared with levels above 1.0 nmol/L; the association with CVD (cardiovascular disease) events did not reach significance.
Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - Vlasschaert et al., 2020

Systematic review of 9 RCTs (randomized controlled trials, gold-standard clinical studies with random participant assignment). Vitamin K supplementation did not consistently slow progression of arterial calcification, atherosclerosis, or arterial stiffness, although there was some signal of benefit in participants with established calcification. MGP (matrix Gla protein, a calcification inhibitor in bone and vessel walls) carboxylation status improved consistently with supplementation.
The effect of vitamin K supplementation on cardiovascular risk factors: a systematic review and meta-analysis - Zhao et al., 2024

Meta-analysis of 17 RCTs. Vitamin K supplementation significantly reduced HOMA-IR (homeostatic model assessment of insulin resistance, a calculated measure of insulin sensitivity) compared with placebo, with subgroup analysis showing that vitamin K1 specifically reduced HOMA-IR. No significant pooled effects were observed on lipid profile, CRP (C-reactive protein, a blood marker of inflammation), or fasting glucose.
Vitamin K intake and the risk of fractures: A meta-analysis - Hao et al., 2017

Meta-analysis of 5 cohort and nested case-control studies (more than 80,000 participants, 1,114 fractures). Higher dietary vitamin K1 intake was associated with 22% lower fracture risk (RR (relative risk, the ratio of event probability between groups) 0.78; 95% CI 0.56–0.99). A dose-response analysis suggested approximately 3% lower fracture risk per 50 mcg/day increment in K1 intake.

Mechanism of Action

Vitamin K1 exerts its biological effects through the vitamin K cycle, a recycling system that allows the body to reuse small amounts of vitamin K many times.

Gamma-carboxylation of vitamin K-dependent proteins: Vitamin K1 acts as an essential cofactor for GGCX (gamma-glutamylcarboxylase, the enzyme that activates vitamin K-dependent proteins). GGCX converts specific glutamic acid residues to gamma-carboxyglutamic acid residues on target proteins, enabling them to bind calcium ions and become biologically active. During this reaction, the reduced (hydroquinone) form of vitamin K is oxidized to vitamin K epoxide.
Vitamin K cycle recycling: VKOR (vitamin K epoxide reductase, the enzyme that recycles vitamin K) reduces vitamin K epoxide back to the active hydroquinone form, allowing the vitamin to be reused repeatedly. This recycling explains why daily vitamin K requirements are quantitatively small. Warfarin and related VKAs (vitamin K antagonists, drugs that inhibit vitamin K recycling) work by inhibiting VKOR, producing a functional vitamin K deficiency.
Hepatic coagulation factor activation: Vitamin K1 is preferentially taken up by the liver, where it activates coagulation factors II (prothrombin), VII, IX, and X, and the anticoagulant proteins C, S, and Z. Without adequate K1, these proteins cannot bind calcium and the coagulation cascade fails, producing bleeding risk.
Bone metabolism: Vitamin K1 activates osteocalcin, a vitamin K-dependent protein produced by osteoblasts (bone-building cells) that helps incorporate calcium into the bone matrix. Undercarboxylated osteocalcin (ucOC, an inactive form of osteocalcin used as a functional marker of vitamin K status) cannot bind calcium effectively, weakening bone mineralization.
Vascular calcification inhibition: MGP, the most potent known inhibitor of soft-tissue calcification, also requires vitamin K-dependent gamma-carboxylation. When vitamin K status is insufficient, MGP remains undercarboxylated and cannot prevent the deposition of calcium phosphate crystals in arterial walls. K1 contributes to MGP activation, although vitamin K2 menaquinones may be more efficient at carboxylating extrahepatic vitamin K-dependent proteins.
Anti-inflammatory and antioxidant signalling: Preclinical and emerging clinical data suggest vitamin K can suppress NF-κB (nuclear factor kappa-B, a transcription factor that drives inflammatory gene expression) signalling and reduce production of pro-inflammatory cytokines such as IL-6 (interleukin-6, an inflammatory signalling molecule) and TNF-α (tumor necrosis factor-alpha, a key inflammatory protein). Vitamin K may also act directly as a redox-cycling antioxidant in lipid membranes.

Pharmacological properties: Phylloquinone is highly lipophilic. After absorption from the small intestine in the presence of bile and dietary fat, it is transported in chylomicrons and chylomicron remnants and concentrated in the liver. Plasma half-life is short, on the order of 8–24 hours. Catabolism is dominated by CYP4F2 (cytochrome P450 4F2, a liver enzyme that hydroxylates and inactivates vitamin K1) with subsequent UGT (UDP-glucuronosyltransferase, an enzyme family that conjugates substrates for biliary or urinary excretion) conjugation; biliary excretion is the main elimination route.

Historical Context & Evolution

Vitamin K was discovered in 1929 by Danish biochemist Henrik Dam, who observed that chicks fed a fat-free diet developed hemorrhagic disease that could be reversed by a fat-soluble factor in green leaves. He named the factor “Koagulationsvitamin” (vitamin K). Dam and American biochemist Edward Doisy, who elucidated its chemical structure, shared the 1943 Nobel Prize in Physiology or Medicine.

Vitamin K1 itself was first isolated from alfalfa by Doisy’s group in 1939, and Louis Fieser achieved its total synthesis the same year. For roughly four decades thereafter, vitamin K was understood almost exclusively as a coagulation cofactor, with clinical use limited to treating hemorrhagic disease of the newborn and reversing warfarin overdose.

The modern era of vitamin K research began in the 1970s and 1980s with the discovery of the gamma-carboxylation mechanism and the identification of non-coagulation vitamin K-dependent proteins, including osteocalcin (1975) and MGP (1983). These discoveries established that vitamin K’s biological role extends well beyond clotting. The subsequent recognition of subclinical vitamin K insufficiency — adequate for hepatic coagulation factor synthesis but insufficient for full activation of extrahepatic vitamin K-dependent proteins — drove renewed interest in vitamin K optimization as a longevity strategy. This perspective is supported by Bruce Ames’ “triage theory”, which proposes that the body prioritizes scarce micronutrients for short-term survival functions (such as coagulation) at the expense of long-term tissue maintenance (such as bone and vascular health). The current period is characterized by an active debate over whether population-level vitamin K1 intakes considered “adequate” are in fact optimal, and how the K1 and K2 forms should be combined.

Expected Benefits

High 🟩 🟩 🟩

Blood Coagulation Support

Vitamin K1 is essential for the hepatic synthesis of functional coagulation factors II, VII, IX, and X. Without adequate vitamin K1, the coagulation cascade cannot proceed normally, producing prolonged clotting times and bleeding risk. This is the most well-established function of vitamin K1 and the basis for its clinical use in treating vitamin K deficiency bleeding in newborns and reversing warfarin-induced coagulopathy. For health- and longevity-oriented adults this benefit is rarely the primary motivation but underpins the entire clinical experience with the nutrient.

Magnitude: Essential cofactor; clinical deficiency produces measurable coagulopathy within days to weeks. AI values (90–120 mcg/day) fully support coagulation in healthy adults.

Medium 🟩 🟩

Fracture Risk Reduction

Multiple observational studies and meta-analyses link higher dietary vitamin K1 intake with lower fracture risk. A meta-analysis of cohort studies found a 22% lower fracture risk in those with the highest versus lowest vitamin K1 intake, with a dose-response of roughly 3% per 50 mcg/day (PMID 28445289). The proposed mechanism is K1’s activation of osteocalcin, enabling proper calcium binding into the bone matrix. A long-term RCT in postmenopausal women using 5 mg/day phylloquinone reported a significant reduction in clinical vertebral fractures, although bone density itself changed little. For midlife and older adults — particularly postmenopausal women — this benefit is directly relevant.

Magnitude: Approximately 22% lower fracture risk for highest versus lowest intake (observational); ~3% reduction per 50 mcg/day; significant reduction in clinical vertebral fractures in one large RCT at 5 mg/day.

All-Cause Mortality Reduction

A participant-level meta-analysis of three large US cohorts found that adults with the lowest circulating phylloquinone had a 19% higher all-cause mortality risk over a median of 13 years compared with those with the highest levels (PMID 32359159). Earlier prospective work in high-cardiovascular-risk populations also reported lower mortality in those with the highest vitamin K intakes. These findings are consistent across cohorts and biologically plausible via vitamin K-dependent protein activation, but no RCT has yet directly tested whether vitamin K1 supplementation reduces mortality, and confounding by overall dietary quality cannot be excluded.

Magnitude: 19% higher all-cause mortality with low circulating phylloquinone (participant-level meta-analysis); broadly consistent direction of effect across cohorts. No RCT mortality data.

Coronary Heart Disease Risk Reduction ⚠️ Conflicted

A meta-analysis of prospective cohort studies found that higher dietary phylloquinone intake was associated with an 8% lower risk of coronary heart disease (HR 0.92; 95% CI 0.84–0.99) (PMID 31119401), and elevated dp-ucMGP (a marker of functional vitamin K deficiency) tracks with both CVD and all-cause mortality. RCTs targeting cardiovascular endpoints, however, have not consistently demonstrated benefit, and a systematic review of 9 controlled trials concluded that vitamin K supplementation does not reliably slow calcification or atherosclerosis at the population level (PMID 32977548). The discrepancy may reflect short trial durations, under-powered hard-endpoint analyses, and recruitment of populations with low baseline calcification.

Magnitude: ~8% lower CHD risk per highest versus lowest dietary intake (observational); RCT evidence for hard cardiovascular endpoints remains inconclusive.

Low 🟩

Vascular Calcification Slowing ⚠️ Conflicted

Vitamin K1 activates MGP, the body’s primary inhibitor of vascular calcification. A 3-year RCT of 500 mcg/day phylloquinone in older adults found ~6% less coronary artery calcification progression in adherent participants with pre-existing calcification (PMID 19386744). However, the broader systematic review of vitamin K trials found inconsistent effects on calcification across studies, with the strongest signal restricted to those with established disease (PMID 32977548). For longevity-oriented adults at risk of arterial calcification, the rationale is mechanistically strong but the human RCT evidence remains mixed.

Magnitude: ~6% less CAC (coronary artery calcification, a CT (computed tomography, a medical imaging technique)-measured score of calcified plaque burden) progression in adherent users with pre-existing calcification; inconsistent results across the trial literature overall.

Insulin Sensitivity Improvement

A meta-analysis of 17 RCTs found that vitamin K supplementation significantly reduced HOMA-IR, although subgroup analysis attributed the significant effect to vitamin K2 rather than vitamin K1 (PMID 38282652). The proposed mechanism involves vitamin K-dependent activation of osteocalcin, which has insulin-sensitizing endocrine effects, and modulation of inflammatory signalling. Direct K1-specific evidence for insulin sensitivity is therefore limited, and most trials are short.

Magnitude: Pooled HOMA-IR reduction (WMD (weighted mean difference, a pooled effect-size measure across studies) ≈ -0.24); modest improvements in fasting glucose and HbA1c (glycated hemoglobin, a measure of average blood sugar over 2–3 months) in some subgroups; clinical significance still uncertain.

Bone Mineral Density Preservation

A meta-analysis of RCTs combining vitamin K with calcium found a small but significant increase in lumbar spine BMD (bone mineral density, a measure of bone strength) and significant reductions in undercarboxylated osteocalcin, although the K1-only subgroup effect on BMD did not reach significance (PMID 34649591). An older systematic review of 13 trials found that nearly all reported phylloquinone benefit on bone-loss markers (PMID 16801507). The signal is more reliable for biochemical bone markers than for densitometry.

Magnitude: Small improvement in lumbar spine BMD with combined K + calcium; consistent reductions in undercarboxylated osteocalcin across most trials; K1-only BMD effect not reliably distinguishable from placebo.

Speculative 🟨

Anti-Inflammatory and Antioxidant Effects

Preclinical evidence supports anti-inflammatory and antioxidant actions of vitamin K, potentially via NF-κB suppression and direct redox cycling in lipid membranes. Human trials specifically demonstrating clinically meaningful anti-inflammatory benefit of phylloquinone supplementation are limited and inconsistent. The basis here is mechanistic and supported by narrative reviews such as Kazmierczak-Baranska 2024.

Neuroprotective Effects

Vitamin K-dependent proteins (including Gas6 (growth arrest-specific protein 6, a vitamin K-dependent protein involved in cell survival, neuronal signalling, and inflammation)) are expressed in brain tissue, and vitamin K participates in sphingolipid (a class of brain lipids important for cell signalling and membrane structure) metabolism. Observational data link low vitamin K status with poorer cognitive performance in older adults, but interventional evidence specifically for K1 is sparse and most data come from observational cohorts or animal models.

Osteoarthritis Modification

Observational studies link low vitamin K status with greater osteoarthritis prevalence and progression, plausibly via undercarboxylated MGP in cartilage. Active phylloquinone RCTs in knee osteoarthritis are ongoing, but results are not yet available, so any human benefit is currently mechanistic and indirect.

Benefit-Modifying Factors

Genetic polymorphisms: VKORC1 (vitamin K epoxide reductase complex subunit 1, the gene encoding the main vitamin K recycling enzyme) variants — most notably the c.-1639G>A promoter polymorphism — modulate vitamin K recycling efficiency; A-allele carriers tend to have lower vitamin K status at equivalent intake. CYP4F2 V433M (rs2108622) T-allele carriers metabolize phylloquinone more slowly, often achieving higher tissue levels for a given intake. The APOE4 (apolipoprotein E4, a genetic variant affecting lipid transport and Alzheimer’s risk) genotype affects lipoprotein-mediated vitamin K transport and may shift its tissue distribution.
Baseline biomarker levels: Adults with low circulating phylloquinone (<0.5 nmol/L) or elevated dp-ucMGP (indicating functional vitamin K deficiency in extrahepatic tissues) stand to benefit most from supplementation. Those already consuming several daily servings of dark leafy greens (typically ≥200 mcg/day phylloquinone) may see minimal incremental benefit from added K1.
Sex-based differences: Women have lower official adequate intake recommendations (90 mcg/day vs. 120 mcg/day for men) but appear more susceptible to bone-related consequences of vitamin K insufficiency, particularly postmenopausal women in whom estrogen-related bone loss accelerates. The fracture-protective signal of vitamin K1 has been most consistently observed in this population.
Pre-existing health conditions: Adults with fat-malabsorption conditions (celiac disease, Crohn’s disease, cystic fibrosis, short-bowel syndrome) are at materially higher risk of vitamin K1 insufficiency due to impaired uptake of fat-soluble vitamins. Chronic broad-spectrum antibiotic exposure can reduce intestinal menaquinone synthesis and increase reliance on dietary K1. Hepatic disease can impair vitamin K storage and utilization.
Age-related considerations: Older adults (65+) tend to have both lower vitamin K1 intakes and reduced fat absorption, increasing the prevalence of subclinical insufficiency. The bone-protective and vascular calcification-inhibiting benefits are most relevant to this group, in whom osteoporosis and arterial calcification rise sharply.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Interference with Vitamin K Antagonist Anticoagulants

Vitamin K1 directly antagonizes the therapeutic effect of warfarin and other VKAs (vitamin K antagonists, oral anticoagulants such as warfarin, acenocoumarol, and phenprocoumon) by providing substrate for the very coagulation factors these drugs are designed to suppress. Even modest increases in habitual vitamin K intake can destabilize INR (international normalized ratio, a standardized measure of clotting time used to monitor VKA therapy), risking either thrombosis or bleeding. This is the single most clinically significant concern for K1 supplementation and the primary reason for medical supervision in this population.

Magnitude: Clinically meaningful INR changes have been documented with vitamin K intake variations as small as 100–150 mcg/day above habitual intake in warfarin users. Several million adults globally take VKAs.

Low 🟥

Allergic Reactions With Parenteral Administration

Intravenous vitamin K1 (phytonadione) has been associated with anaphylactoid reactions, including bronchospasm and rarely cardiac arrest, at an incidence on the order of ~3 per 10,000 IV treatments. This risk is essentially specific to the parenteral route and the polyethoxylated castor oil vehicle used in some formulations; oral phylloquinone supplementation does not carry this risk.

Magnitude: Approximately 3 per 10,000 IV treatments; effectively zero risk with oral supplementation.

Speculative 🟨

Theoretical Concerns at Very High Doses

No tolerable upper limit has been set for vitamin K1 by US, EU, or Japanese authorities, and no oral toxicity has been demonstrated. Phylloquinone at 10 mg/day and menaquinone-7 at 45 mg/day have been used safely for up to two years in clinical trials. Theoretical concerns about promoting thrombosis in susceptible individuals at very high doses remain unsubstantiated; vitamin K1 supports normal coagulation factor synthesis up to a saturation point and does not cause hypercoagulability in non-VKA users.

Possible Synthetic Menadione (K3) Toxicity

Synthetic menadione (vitamin K3, a synthetic precursor sometimes mislabeled as a vitamin K source in animal feeds) — sometimes confused with K1 in older literature — has been linked to oxidative damage at high doses and is not used in modern human supplements. This is a labeling/identification risk rather than a property of phylloquinone itself.

Risk-Modifying Factors

Genetic polymorphisms: VKORC1 c.-1639 A-allele carriers may be more sensitive to fluctuations in vitamin K1 intake, particularly if also taking warfarin, and may require closer INR monitoring. CYP4F2 V433M T-allele carriers metabolize phylloquinone more slowly, which can magnify the impact of intake changes on warfarin sensitivity.
Baseline biomarker levels: Adults with stable, therapeutic INR on warfarin are most exposed to risk from changes in vitamin K intake. Those not on anticoagulants face essentially no known risk from phylloquinone at typical supplemental doses.
Sex-based differences: No significant sex-based differences in K1 risk have been demonstrated beyond population-level differences in warfarin use and indications for anticoagulation.
Pre-existing health conditions: Individuals on warfarin or other VKAs, those with a recent major thrombotic event being managed with anticoagulation, and those with advanced hepatic disease (where vitamin K kinetics may be unpredictable) require medical supervision before supplementing.
Age-related considerations: Older adults are more likely to be on VKAs and to have multiple drug interactions, raising the practical relevance of the warfarin interaction. The intrinsic safety profile of oral phylloquinone, however, does not change with age.

Key Interactions & Contraindications

Prescription drug interactions:
- Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon): Direct pharmacological antagonism. Caution / under medical supervision only. Consequence: destabilized INR, with risk of either bleeding or thrombosis. Mitigation: maintain a consistent daily vitamin K intake rather than starting/stopping supplements; check INR within 1–2 weeks of any change in vitamin K intake.
- DOACs (direct oral anticoagulants, newer blood thinners such as apixaban, rivaroxaban, edoxaban, and dabigatran): No clinically meaningful interaction; these agents do not depend on vitamin K-mediated factors. No mitigation required.
- Orlistat (a lipase inhibitor used for weight management): Caution. Reduces fat absorption and can lower vitamin K1 absorption with chronic use. Mitigation: separate dosing and consider monitoring vitamin K status if orlistat is used long-term.
- Bile acid sequestrants (cholestyramine, colestipol, colesevelam): Caution. Reduce absorption of fat-soluble vitamins, including K1. Mitigation: separate administration by ≥4 hours.
- Broad-spectrum antibiotics (long-term): Caution. May reduce intestinal menaquinone-producing bacteria and unmask marginal K1 intake. Mitigation: ensure consistent dietary K1 during prolonged courses.
Over-the-counter medication interactions:
- High-dose vitamin E (>800 IU/day alpha-tocopherol): Caution. May antagonize vitamin K-dependent carboxylation and increase bleeding risk, particularly in K-depleted individuals. Mitigation: avoid sustained supratherapeutic vitamin E doses if K1 status is marginal.
- Mineral oil laxatives: Caution. Chronic use can reduce K1 absorption. Mitigation: limit chronic mineral oil use; favor non-lipid-based laxatives.
Supplement interactions:
- Vitamin D3 (cholecalciferol): Synergistic for bone and vascular health. Vitamin D upregulates vitamin K-dependent proteins such as osteocalcin and MGP, which K1 then activates. Mitigation: co-supplementation is logical, not a problem to manage.
- Calcium (e.g., as carbonate or citrate): Synergistic for bone health when paired with adequate K1 (and ideally K2). No mitigation required beyond standard calcium dosing recommendations.
- Vitamin K2 menaquinones (MK-4, MK-7): Complementary, not competitive. K1 is preferentially used by the liver for coagulation; K2 (especially MK-7) preferentially reaches extrahepatic tissues. Combined K1 + K2 products address both pools.
- Omega-3 fatty acids (EPA & DHA), magnesium, CoQ10 (coenzyme Q10, a mitochondrial antioxidant): No clinically meaningful interaction with vitamin K1.
Other intervention interactions:
- Very-low-fat diets: Functional interaction. Phylloquinone absorption depends on dietary fat; very-low-fat regimens may blunt absorption from both food and supplements. Mitigation: pair K1 with a meal containing some fat.
Populations who should avoid this intervention:
- Adults on warfarin or other VKAs without prescriber oversight — absolute contraindication to ad-hoc supplementation.
- Adults with a recent major thrombotic event (e.g., DVT (deep vein thrombosis, a blood clot in a deep vein, usually in the leg)/PE (pulmonary embolism, a blood clot that has travelled to the lungs) within the past 90 days) being managed with anticoagulation — supplement only under physician guidance.
- Adults with severe hepatic dysfunction (e.g., Child-Pugh Class C cirrhosis) — supplement only under physician guidance owing to unpredictable vitamin K kinetics.

Risk Mitigation Strategies

Consult before supplementing if on anticoagulants: Anyone taking warfarin or another VKA should discuss vitamin K1 supplementation with their prescriber before starting. This mitigates the principal risk — INR destabilization — by allowing dose recalibration and monitoring rather than uncontrolled exposure changes.
Start at dietary-level doses: Begin supplementation at 100–200 mcg/day, which approximates the AI of 90–120 mcg/day. Doses in this range are extremely unlikely to produce adverse effects in any non-VKA population and avoid the need for INR re-titration.
Take with dietary fat: Consume phylloquinone supplements alongside a meal containing fat (for example olive oil, nuts, eggs, or avocado). This addresses the malabsorption-related risk of ineffective supplementation, since K1 bioavailability is several-fold higher with fat than on an empty stomach.
Maintain consistent intake: Use the same daily dose at the same time of day rather than intermittent or weekend-only dosing. Consistency mitigates the destabilization risk for any future VKA prescription and produces steadier vitamin K-dependent protein activation.
Recheck INR within 1–2 weeks of any change in K1 intake (VKA users): If supplementation is initiated, stopped, or dose-changed in someone on warfarin, INR should be reassessed within 1–2 weeks and periodically thereafter until stable. This mitigates the bleeding/thrombosis risk associated with INR drift.
Pair with vitamin K2 where appropriate: For those whose primary objective is bone or vascular benefit rather than coagulation support, combining K1 with K2 (typically MK-7 90–180 mcg/day) reduces the risk of “intervention failure” — i.e., adequate hepatic carboxylation but persistently undercarboxylated extrahepatic vitamin K-dependent proteins.
Verify product identity and label accuracy: Choose third-party-tested products and confirm the form is phylloquinone (vitamin K1) rather than menadione (K3). This mitigates the labeling/identification risk associated with synthetic menadione exposure and the risk of underdosing from inaccurate label claims.

Therapeutic Protocol

The most widely referenced approach to vitamin K1 supplementation in adults aged 45–65 is informed by the Linus Pauling Institute’s nutritional guidance and by clinical trial dosing in bone- and vascular-focused trials.

Basic maintenance dose: 100–200 mcg/day phylloquinone — meets or exceeds the AI of 90–120 mcg/day and provides a margin for those with suboptimal dietary intake.
Bone- and vascular-optimization dose: 500–1,000 mcg/day phylloquinone — the dose range used in the major RCTs reporting fracture-rate and calcification effects.
Clinical research dose: Up to 5 mg (5,000 mcg)/day, used in some fracture-prevention trials, but reserved for physician-directed protocols.

A complementary, integrative-medicine variant of this protocol pairs K1 with K2 (typically MK-7 90–180 mcg/day) and vitamin D3, on the premise that K1 alone may not optimally activate extrahepatic vitamin K-dependent proteins. Both approaches are common in practice; neither is uniquely “the” standard. Clinicians associated with the Linus Pauling Institute and integrative practitioners influenced by Kate Rheaume-Bleue and Bruce Ames have been particularly visible in popularizing the K1 + K2 + D3 combination.

Best time of day: Take with the largest meal of the day that contains dietary fat (typically lunch or dinner). There is no evidence of meaningful time-of-day effects on efficacy, and vitamin K1 does not influence sleep.

Half-life: Plasma half-life is on the order of 8–24 hours, considerably shorter than long-chain menaquinones such as MK-7 (~72 hours), which supports daily — rather than weekly — dosing for stable plasma levels.

Single vs. split doses: At typical supplemental doses (100–1,000 mcg), a single daily dose with a fat-containing meal is sufficient. Splitting is unnecessary because absorption is efficient and the vitamin K cycle recycles each molecule many times.

Genetic polymorphisms: Adults with the VKORC1 c.-1639 A/A genotype have reduced vitamin K recycling efficiency and may benefit from the upper end of the maintenance range. CYP4F2 V433M T-allele carriers metabolize phylloquinone more slowly, potentially achieving adequate tissue levels at lower doses. APOE4 carriers may have altered tissue distribution, but specific dose modifications are not well established.

Sex-based differences: Postmenopausal women may benefit from doses in the bone-optimization range (500–1,000 mcg/day) given accelerated bone loss after menopause. Men have a higher AI (120 mcg/day vs. 90 mcg/day), reflecting larger body mass, but the same supplemental ranges apply.

Age-related considerations: Adults over 65 should consider supplementation in the bone- and vascular-optimization range (500–1,000 mcg/day) given the high prevalence of subclinical insufficiency and accelerating osteoporosis and arterial calcification in this age group. Those with reduced fat absorption should explicitly take K1 with a fat source.

Baseline biomarker levels: Individuals with measured low circulating phylloquinone (<0.5 nmol/L) or elevated dp-ucMGP should target the higher end of supplementation. Those already consuming multiple servings of dark leafy greens daily (200–500+ mcg/day phylloquinone equivalent) may need only minimal additional supplementation.

Pre-existing health conditions: Adults with fat-malabsorption conditions may need higher doses or emulsified/micellized formulations. Adults on warfarin or other VKAs should not initiate supplementation without prescriber guidance and INR monitoring.

Discontinuation & Cycling

Vitamin K1 is intended for continuous daily intake as part of a nutritional regimen, not a cycled drug protocol. Because it is an essential nutrient with no demonstrated oral toxicity, there is no physiological rationale for periodic discontinuation.

Lifelong vs. short-term: Continuous lifelong intake (from food and/or supplementation) is appropriate. Short-term courses are reserved for clinical scenarios such as reversing warfarin or correcting documented deficiency.
Withdrawal effects: None documented on stopping oral phylloquinone. There is no rebound coagulopathy in non-VKA users; those previously relying on supplementation to compensate for poor dietary intake will gradually return to their prior subclinical-insufficiency state over days to weeks.
Tapering: Not necessary in non-VKA users — abrupt discontinuation is safe. In warfarin users who discontinue K1 supplementation, INR should be rechecked within 1–2 weeks because warfarin sensitivity will rise as vitamin K input falls.
Cycling: Not recommended or required. There is no efficacy loss with continuous use, no receptor desensitization, and no accumulation toxicity that would justify a cycling schedule.

Sourcing and Quality

Preferred form: Phylloquinone (vitamin K1) — chemically identical to the dietary form. Available as a standalone supplement, but more commonly bundled with vitamin K2 (MK-4 and/or MK-7) and/or vitamin D3 in “bone and vascular” formulations.
Third-party testing: Look for products independently verified by USP (United States Pharmacopeia, a non-profit standards body for medicines and supplements), NSF International (a public-health certification body that tests dietary supplements), or ConsumerLab. ConsumerLab testing has documented label-claim shortfalls in some K products, making third-party verification meaningful.
Reputable brands: Among standalone or combined K1/K2 products, Life Extension, Thorne, NOW Foods, and Carlson have generally performed well in independent testing. Combined formulations such as Life Extension’s Super K and Thorne’s vitamin K products are widely used.
Avoid menadione (K3): Modern human supplements should contain phylloquinone (K1) and/or menaquinones (K2), not menadione (K3), which is a synthetic precursor used in animal feeds and is not appropriate for human supplementation.
Dietary sources: The richest food sources of K1 are dark leafy greens — kale, collard greens, spinach, Swiss chard, turnip greens, and broccoli — followed by parsley, Brussels sprouts, and certain plant oils (notably soybean and canola). One cup of cooked kale typically provides several hundred mcg to >1,000 mcg of K1, well above the AI.

Practical Considerations

Time to effect: Coagulation effects of K1 repletion appear within 6–12 hours and are clinically used to reverse warfarin. Improvements in vitamin K-dependent protein carboxylation status (for example, undercarboxylated osteocalcin) are typically detectable within 2–4 weeks. Bone-related benefits require months to years of consistent intake; vascular calcification effects, where seen, required 2–3 years in clinical trials.
Common pitfalls: Taking K1 on an empty stomach (substantially reducing absorption); confusing K1 with K2 and assuming one form covers all functions; assuming dietary adequacy from greens without accounting for the low (~5–10%) absorption of food-bound phylloquinone; supplementing while on warfarin without medical guidance; and switching brands or dose intermittently in ways that destabilize INR in VKA users.
Regulatory status: Vitamin K1 is sold over-the-counter as a dietary supplement and is also available as a prescription medication (injectable phytonadione) used to treat vitamin K deficiency bleeding and reverse warfarin. No tolerable upper limit has been set for the natural K1 form.
Cost and accessibility: Phylloquinone supplements are inexpensive and widely available in pharmacies, supermarkets, and online retailers. A year’s supply at 100–1,000 mcg/day typically costs roughly USD 5–20 for standalone K1 and USD 15–40 for combined K1/K2 products.

Interaction with Foundational Habits

Sleep: No direct interaction. Vitamin K1 has no documented effects on sleep architecture, melatonin secretion, or circadian rhythm and can be taken at any time of day without affecting sleep. Indirectly, by supporting vascular and bone health it may reduce nocturnal discomfort related to musculoskeletal or vascular conditions in older adults, but this is not a primary effect.
Nutrition: Direct, potentiating interaction. Phylloquinone absorption is critically dependent on dietary fat — co-administration with a meal containing fat increases bioavailability several-fold compared with fasting administration. Diets rich in dark leafy greens (kale, spinach, collard greens, Swiss chard) supply substantial K1, although only ~5–10% is absorbed; pairing greens with olive oil, nuts, or eggs improves uptake. Vitamin K1 also acts synergistically with vitamin D3 and calcium for bone health, since vitamin D upregulates the vitamin K-dependent proteins that K1 activates. Very-low-fat diets blunt this synergy.
Exercise: Indirect, supportive interaction. Vitamin K1 has no documented blunting effect on exercise adaptations, hypertrophy, or aerobic conditioning, and there are no specific timing considerations relative to training. The most relevant interaction is with bone-loading (resistance training, impact, walking), which combines mechanically with adequate K1 status to support bone mineralization via vitamin K-dependent osteocalcin activation.
Stress management: Indirect, mostly speculative interaction. No direct effect on cortisol or the HPA (hypothalamic-pituitary-adrenal, the body’s central stress response system) axis has been established. The emerging evidence on vitamin K’s anti-inflammatory properties (NF-κB and cytokine modulation) suggests a possible secondary role in dampening stress-related chronic inflammation, but this is mechanistic rather than clinically demonstrated.

Monitoring Protocol & Defining Success

Baseline assessment is recommended before initiating supplementation, particularly for adults specifically targeting bone or vascular endpoints. Repeat ongoing monitoring at 3–6 months after dose stabilization and then every 6–12 months, with additional INR checks within 1–2 weeks of any change in K1 intake in VKA users.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Plasma phylloquinone (vitamin K1)	0.5–2.0 nmol/L	Direct measure of vitamin K1 status	Fasting sample; conventional reference range typically 0.2–3.2 nmol/L; <0.5 nmol/L is associated with higher mortality in cohort data
dp-ucMGP	<500 pmol/L	Functional marker of vitamin K sufficiency for vascular tissue	Elevated values indicate insufficient K activation of MGP and track with CVD mortality risk; not yet widely available outside research labs
Undercarboxylated osteocalcin (ucOC, % of total)	<20%	Functional marker of vitamin K sufficiency for bone tissue	Conventional labs often report only total osteocalcin; ucOC requires a specific assay
INR (international normalized ratio)	0.9–1.1 (off VKAs); per prescriber target on VKAs	Confirms adequate (and unchanging) coagulation status	Essential baseline for anyone considering supplementation; fasting not required; the target on VKAs is set by the prescribing clinician
Vitamin D, 25-hydroxy	40–60 ng/mL	Ensures adequate vitamin D for synergistic K-D bone effects	Conventional reference 30–100 ng/mL; functional optimal 40–60 ng/mL; fasting not required

Baseline laboratory testing — phylloquinone, dp-ucMGP where available, ucOC where available, INR, and 25-hydroxy vitamin D — should be obtained before starting supplementation to anchor later changes.

Ongoing monitoring should follow the cadence of an INR re-check within 1–2 weeks of any change in vitamin K1 intake for VKA users; recheck of plasma phylloquinone, dp-ucMGP, and ucOC at 3–6 months after dose stabilization; repeat 25-hydroxy vitamin D every 6–12 months; and a DEXA (dual-energy X-ray absorptiometry, the standard bone density scan) scan at baseline and at 1–2 years if bone health is a primary objective.

Qualitative markers worth tracking subjectively include:

absence of easy bruising or unusual bleeding;
stable or reduced vascular calcification scores on CT (over 2–3 years);
improved or stable bone density on DEXA (over 1–2 years);
general indicators of musculoskeletal resilience — recovery from minor falls, ease of weight-bearing activity.

Because vitamin K1’s benefits are predominantly preventive and operate over long timeframes, subjective improvements are expected to be subtle relative to interventions with more immediate effects.

Emerging Research

Vitamin K and knee osteoarthritis (subtype comparison): A pilot RCT (NCT06385275) is comparing different vitamin K subtypes and doses (phylloquinone 500–1,000 mcg/day vs. MK-7 300 mcg/day) in older adults with knee osteoarthritis, measuring biochemical response (e.g., ucMGP (uncarboxylated matrix Gla protein, the inactive form of MGP that accumulates when vitamin K is insufficient)) and physical function in approximately 55 participants.
Vitamin K1 for osteoarthritis function: A double-blind pilot trial (NCT05505552) is evaluating 1 mg/day phylloquinone versus placebo for 6 months in adults with knee osteoarthritis and low vitamin K status, assessing physical function and MGP genotype effects in roughly 37 participants.
Vitamin K and cognition in coronary heart disease: A pilot study (NCT06855953) is assessing the effect of vitamin K supplementation on cognitive performance and vascular function in adults with stable coronary heart disease (~40 participants, pilot phase).
Vitamin K bioavailability comparison: A crossover study (NCT07041645) using 13C-labelled vitamin K vitamers will compare the bioavailability of phylloquinone, MK-4, MK-7, and MK-9 in humans, potentially informing optimal supplementation form selection (~20 participants).
Triage-theory framework for K1 sufficiency: The McCann & Ames triage paper on vitamin K (PMID 19692494) proposes that the body prioritizes scarce micronutrients for short-term survival functions (such as coagulation) at the expense of long-term tissue maintenance (such as bone and vascular health). This provides a unifying framework for interpreting subclinical vitamin K1 insufficiency in cohort studies and motivates longer-duration trials that target hard endpoints such as fractures and cardiovascular events.
Aging-biology-focused review: The 2024 narrative review (The Protective Role of Vitamin K in Aging and Age-Related Diseases, Kazmierczak-Baranska et al.) consolidates molecular evidence on vitamin K’s anti-inflammatory and antioxidant actions and explicitly frames vitamin K as a candidate intervention against multiple age-related diseases. Future trials testing K1 (or K1 + K2) against composite aging endpoints — e.g., frailty, cardiovascular events, and fractures — could meaningfully shift the case for routine supplementation in either direction.

Conclusion

Vitamin K1 (phylloquinone) is an essential, fat-soluble vitamin with biological roles extending well beyond blood coagulation. The strongest evidence supports its central role in clotting, an association between low circulating phylloquinone and higher all-cause mortality, and a meaningful link between higher dietary K1 intake and lower fracture risk. Evidence for slowing arterial calcification, improving insulin sensitivity, and preserving bone mineral density is more modest and, in places, conflicted between observational and trial data.

For health- and longevity-oriented adults, the practical picture is that many people obtain just enough K1 to maintain normal clotting but not enough to fully activate the proteins that protect bone and the vascular wall. Supplementation in the 100–1,000 mcg/day range — particularly when paired with vitamin D3, calcium, and (often) vitamin K2 — is mechanistically grounded and supported by intermediate-quality clinical evidence, with stronger signals for those with low baseline status or established calcification.

The safety profile is exceptional: no tolerable upper limit has been set, oral toxicity has not been demonstrated, and the only major concern is interference with warfarin and other vitamin K antagonists, which requires medical oversight. Outside that population, vitamin K1 represents a low-risk, low-cost nutritional lever for closing a common gap between adequacy and optimality.

Top - Benefits - Risks - Protocol

Vitamin K1 for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Blood Coagulation Support

Medium 🟩 🟩

Fracture Risk Reduction

All-Cause Mortality Reduction

Coronary Heart Disease Risk Reduction ⚠️ Conflicted

Low 🟩

Vascular Calcification Slowing ⚠️ Conflicted

Insulin Sensitivity Improvement

Bone Mineral Density Preservation

Speculative 🟨

Anti-Inflammatory and Antioxidant Effects

Neuroprotective Effects

Osteoarthritis Modification

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Interference with Vitamin K Antagonist Anticoagulants

Low 🟥

Allergic Reactions With Parenteral Administration

Speculative 🟨

Theoretical Concerns at Very High Doses

Possible Synthetic Menadione (K3) Toxicity

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion